TheraRadar
← Back
Data updated: Jun 28, 2026

MPP PHARMA

Generics

MPP PHARMA is a generic drug manufacturer focused on Neurology, Gastroenterology, Cardiovascular.

1959
Since
20
Drugs
-
Trials
0
New Drugs (2yr)
Modality:

MPP PHARMA's Key Drugs

MPP PHARMA's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

MPP PHARMA's Recent FDA Approvals

New NDA/BLA approvals for MPP PHARMA over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

MPP PHARMA's Therapeutic Areas

MPP PHARMA's approved drugs and pipeline span 5 therapeutic areas, led by Neurology and Gastroenterology, across 0 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Neurology 25%
2 drugs
Gastroenterology 25%
2 drugs
Cardiovascular 25%
2 drugs
Immunology 13%
1 drugs
Infectious Disease 13%
1 drugs

MPP PHARMA Pipeline Snapshot

Active clinical trials for MPP PHARMA across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • Top drug revenue breakdown
  • Drug-level revenue analysis

Trial Catalysts

  • Neurology pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling